Novartis' new CEO, Vasant Narasimhan, has indicated that the company might spin off its struggling U.S. generic pill business—and that is what it is preparing to do, sources are telling Reuters.Original Article
Novartis is preparing to sell its U.S. generics pills business: Reuters
